BRCA1/2 Reversion Mutations and Cancer Therapy Resistance

Area of Science:

• Genetics and Genomics
• Cancer Biology
• Molecular Oncology

Background:

• Germline loss-of-function mutations in BRCA1 and BRCA2 significantly elevate susceptibility to breast, ovarian, and other cancers.
• BRCA2 is essential for RAD51 recruitment to DNA damage sites, while BRCA1 regulates homologous recombination repair (HRR) and DNA damage response signaling.
• Poly (ADP-ribose) polymerase inhibitors (PARPis) exploit synthetic lethality in homologous recombination-deficient tumors, showing clinical benefit in BRCA1/2-mutated cancers.

Purpose of the Study:

• To review the structural and functional domains of BRCA1/2.
• To analyze pathogenic mutation profiles of BRCA1/2.
• To discuss therapeutic strategies for BRCA1/2-deficient cancers and identify knowledge gaps.

Main Methods:

• Literature review of BRCA1/2 function, mutations, and therapeutic strategies.
• Analysis of existing data on PARPi efficacy and resistance mechanisms.
• Synthesis of information on the role of specific BRCA1/2 domains and residual protein activities.

Main Results:

• PARPi therapy is effective in BRCA1/2-mutated cancers, but resistance, often due to secondary mutations restoring protein function, is a significant challenge.
• Critical gaps remain in understanding how specific BRCA1/2 domains and residual protein activities influence tumorigenesis and treatment response.
• Pathogenic mutation profiles highlight the importance of precise genetic alterations in disease susceptibility and therapeutic outcomes.

Conclusions:

• Further functional studies of BRCA1/2 variants are essential for refining cancer risk prediction.
• Developing mutation-tailored therapies is necessary to improve treatment efficacy for BRCA1/2-deficient cancers.
• Addressing resistance mechanisms and understanding the impact of specific BRCA1/2 domains will advance precision oncology.